Related references
Note: Only part of the references are listed.THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: CATALYTIC RECEPTORS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein
Guan Wang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Oridonin Up-regulates Expression of P21 and Induces Autophagy and Apoptosis in Human Prostate Cancer Cells
Xiang Li et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Autophagy-related Gene 7 (ATG7) and Reactive Oxygen Species/Extracellular Signal-regulated Kinase Regulate Tetrandrine-induced Autophagy in Human Hepatocellular Carcinoma
Ke Gong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1)
Jessie-F Fecteau et al.
MOLECULAR MEDICINE (2012)
The role of oxidized cytochrome c in regulating mitochondrial reactive oxygen species production and its perturbation in ischaemia
Philippe Pasdois et al.
BIOCHEMICAL JOURNAL (2011)
Navitoclax (ABT-263) Accelerates Apoptosis during Drug-Induced Mitotic Arrest by Antagonizing Bcl-xL
Jue Shi et al.
CANCER RESEARCH (2011)
Navitoclax Enhances the Efficacy of Taxanes in Non-Small Cell Lung Cancer Models
Nguyen Tan et al.
CLINICAL CANCER RESEARCH (2011)
Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma
Ke Gong et al.
FREE RADICAL BIOLOGY AND MEDICINE (2011)
Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma
Chaoyang Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Bax Activation by Engagement with, Then Release from, the BH3 Binding Site of Bcl-xL
F. Gautier et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma
Qingjun Liu et al.
MOLECULAR CANCER (2011)
Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy
Ryuji Yamaguchi et al.
PLOS ONE (2011)
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
J. C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Carol Kilkenny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Diminished Sensitivity of Chronic Lymphocytic Leukemia Cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood
Meike Vogler et al.
CLINICAL CANCER RESEARCH (2010)
Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3
Kuen-Feng Chen et al.
CLINICAL CANCER RESEARCH (2010)
Menadione triggers cell death through ROS-dependent mechanisms involving PARP activation without requiring apoptosis
Gabriel Loor et al.
FREE RADICAL BIOLOGY AND MEDICINE (2010)
Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo
Gang Wei et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3
Fan Yang et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells
Margaret A. Park et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
Tri K. Nguyen et al.
LEUKEMIA RESEARCH (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
V. Ramakrishnan et al.
ONCOGENE (2010)
Bz-423 superoxide signals B cell apoptosis via Mcl-1, Bak, and Bax
Neal B. Blatt et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2009)
p21(Cip1) protects against oxidative stress by suppressing ER-dependent activation of mitochondrial death pathways
Peter F. Vitiello et al.
FREE RADICAL BIOLOGY AND MEDICINE (2009)
Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
Dong Bai et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Ras Subcellular Localization Defines Extracellular Signal-Regulated Kinase 1 and 2 Substrate Specificity through Distinct Utilization of Scaffold Proteins
Berta Casar et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Direct control of mitochondrial function by mTOR
Arvind Ramanathan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models
Alex R. Shoemaker et al.
CLINICAL CANCER RESEARCH (2008)
Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21WAF1/CIPI dependent
Haiming Ding et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway
W. Zhang et al.
LEUKEMIA (2008)
The BCL-2 protein family: opposing activities that mediate cell death
Richard J. Youle et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Bench-to-bedside review: Mitochondrial injury, oxidative stress and apoptosis - there is nothing more practical than a good theory
Huelya Bayir et al.
CRITICAL CARE (2008)
Basic helix-loop-helix protein E47-mediated p21Waf1/Cip1 gene expression regulates apoptosis of intestinal epithelial cells
Sujoy Bhattacharya et al.
BIOCHEMICAL JOURNAL (2007)
MCL-1 as a buffer for proapoptotic BCL-2 family members during TRAIL-induced apoptosis - A mechanistic basis for sorafenib (bay 43-9006)-induced trail sensitization
Xue Wei Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with mcl-1 and cFLIPL down-regulation
Roberto R. Rosato et al.
CANCER RESEARCH (2007)
Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiation
John P. Plastaras et al.
CANCER RESEARCH (2007)
被撤回的出版物: Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve mcl-1 and p21CIP1 down-regulation(Retracted article. See vol.22, pg.4959,2016)
Girija Dasmahapatra et al.
CLINICAL CANCER RESEARCH (2007)
The Bcl-2 apoptotic switch in cancer development and therapy
J. M. Adams et al.
ONCOGENE (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
被撤回的出版物: The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells (Retracted article. See vol. 79, pg. 5459, 2019)
DJ Panka et al.
CANCER RESEARCH (2006)
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation
M Rahmani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)